Skip to main content

Table 1 Baseline characteristics

From: MRI-guided percutaneous thermoablation in combination with hepatic resection as parenchyma-sparing approach in patients with primary and secondary hepatic malignancies: single center long-term experience

Variables

N (%)/mean ± SD

Age (years)

62.8 ± 9.1

Patients

31

Sex (m/f)

21 (67.8%) / 10 (32.2%)

Number of tumors (ablated/resected)

98 (42/56)

Tumor size of ablated lesions

15.1 ± 7.6 mm

Tumor size of resected lesions

28.7 ± 23.0 mm

Tumor entity

HCC (n = 7)

iCCA (n = 1)

Metastases (n = 23)

 Colorectal carcinoma (n = 17)

  - Left sided (n = 13)

 - Right sided (n = 4)

 Uveal melanoma (n = 3)

 Malignant melanoma (n = 1)

 Breast cancer (n = 1)

 Neuroendocrine tumor (n = 1)

Concomitant liver cirrhosis

5/31 (16.1%);

Child A: n = 3, Child B: n = 2

Liver function (serum levels):

 GOT/GPT (U/I)

45.2 ± 39.0 / 47.5 ± 43.7

 Bilirubin (mg/dl)

0.6 ± 0.3

 Quick-Test (%)

96.6 ± 13.9

  1. HCC Hepatocellular carcinoma, iCCA Intrahepatic cholangiocarcinoma, TACE Transarterial chemoembolization